ArticleDiabetes research and clinical practice2022
How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod® 5 System.
Article in Diabetes research and clinical practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluating the Safety and Effectiveness of the Omnipod Horizon™ Automated Glucose Control System in Patients With Type 1 Diabetes
The diabEAT Study: Insulin dElivery Technologies And eaTing Behaviours in People With Type 1 Diabetes
Who cites it
23 citing papers in PubMed.
- Psychosocial outcomes among adults with type 1 diabetes using a tubeless automated insulin delivery system compared with sensor augmented pump therapy: A randomised, parallel-group clinical trial sub-study.Diabetes, obesity & metabolism · 2026Trial
- Six months of hybrid closed-loop therapy improves diabetes-specific positive well-being, and reduces diabetes distress and fear of hypoglycemia: secondary analysis of a randomized controlled trial.BMJ open diabetes research & care · 2024Trial
- Article
- Transitioning to Omnipod 5Biomedicines · 2026Article
- Despite lower haemoglobin A1c with second-generation automated insulin delivery systems, mental burden remains high for all adults with type 1 diabetes: A BETTER registry analysis.Diabetes, obesity & metabolism · 2026Article
- Automated insulin delivery system use and physical activity levels in adults with type 1 diabetes: A BETTER registry analysis.Diabetic medicine : a journal of the British Diabetic Association · 2026Article
- Comparison of AID users and non-users regarding glycemic control and diabetes distress: A mixed-methods study.PloS one · 2026Article
- Assessment of the added value of a tubeless pump: A time trade-off (TTO) study for utility elicitation of insulin delivery systems in type 1 diabetes mellitus (T1D).Diabetic medicine : a journal of the British Diabetic Association · 2025Article
- Safety, efficacy and psychological impact of Omnipod hybrid closed loop system in children, adolescents, and adults in 24 h and nighttime: Systematic review with additional meta-analysis.Journal of diabetes and metabolic disorders · 2025Review
- Real-world glycemic outcomes of a tubeless automated insulin delivery system: a single-center observational study in Italy.Frontiers in endocrinology · 2025Observational
- Assessing the iLet Bionic Pancreas Deployed in Primary Care and via Telehealth: A Randomized Clinical Trial.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Adults with type 1 diabetes who sleep 7-9 hours per night present lower glycemic variability: a cross-sectional study.Frontiers in endocrinology · 2025Article
- Patient-reported outcomes in studies of diabetes technology: What matters.Diabetes, obesity & metabolism · 2024Review
- Effect of automated insulin delivery systems on person-reported outcomes in people with diabetes: a systematic review and meta-analysis.EClinicalMedicine · 2024Article
- Patient Satisfaction and Clinical Experience With the Tandem t:slim X2 With Control-IQ Technology Advanced Hybrid Closed-Loop Insulin Delivery System.Diabetes spectrum : a publication of the American Diabetes Association · 2024Article
- Relationship between CGM-derived nocturnal hypoglycemia and subjective sleep quality in people with type 1 diabetes.Scientific reports · 2023Article
- The changing landscape of automated insulin delivery in the management of type 1 diabetes.Endocrine connections · 2023Review
- Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States.Journal of managed care & specialty pharmacy · 2023Article
- The Artificial Pancreas and Type 1 Diabetes.The Journal of clinical endocrinology and metabolism · 2023Review
- Differences in positive expectancy of hybrid closed loop (HCL) insulin delivery systems do not explain racial differences in HCL use.Journal of clinical & translational endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
aimsTo evaluate psychosocial outcomes for adults with type 1 diabetes (T1D) using the tubeless Omnipod® 5 Automated Insulin Delivery (AID) System.
methodsA single-arm, multicenter (across the United States), prospective safety and efficacy study of the tubeless AID system included 115 adults with T1D. Participants aged 18-70 years completed questionnaires assessing psychosocial outcomes - diabetes distress (T1-DDS), hypoglycemic confidence (HCS), well-being (WHO-5), sleep quality (PSQI), insulin delivery satisfaction (IDSS), diabetes treatment satisfaction (DTSQ), and system usability (SUS) - before and after 3 months of AID use. Associations among participant characteristics, psychosocial measures and glycemic outcomes were evaluated using linear regression analyses.
resultsAdults using the tubeless AID system demonstrated improvements in diabetes-specific psychosocial measures, including diabetes distress, hypoglycemic confidence, insulin delivery satisfaction, diabetes treatment satisfaction, and system usability after 3 months (all P < 0.001). No changes in general well-being or sleep quality were observed. The psychosocial outcomes assessed were not consistently associated with baseline participant characteristics (i.e., age, sex, diabetes duration, glycemic outcomes including percent time in range 70-180 mg/dL, percent time below range < 70 mg/dL, hemoglobin A1c, or insulin regimen).
conclusionsUse of the Omnipod 5 AID system was associated with significant improvements in diabetes-related psychosocial outcomes for adults with T1D. CLINICAL TRIALS REGISTRATION NUMBER: NCT04196140.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.